Ergoteles’s Adverum Biotechnologies ADVM Stock Holding History

Ergoteles’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,250	Closed	-$47.8K	–	1198
2022 Q4	$47.8K	Sell	8,250 -28,618	-78%	-$217K	﹤0.01%	1297
2022 Q3	$350K	Sell	36,868 -5,112	-12%	-$67.2K	0.01%	908
2022 Q2	$504K	Buy	+41,980	New	+$440K	0.02%	835
2021 Q4	–	Sell	-6,050	Closed	-$131K	–	1203
2021 Q3	$131K	Buy	6,050 +2,330	+63%	+$59.5K	﹤0.01%	1070
2021 Q2	$130K	Buy	+3,720	New	+$200K	﹤0.01%	1363

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Ergoteles's ADVM Position: Q1 2023 in Review

Ergoteles sold out of Adverum Biotechnologies (ADVM) in Q1 2023, closing a stake of 8,250 shares — an estimated $47.8K sold.

Ergoteles first reported a position in ADVM in Q2 2021 and held it in 5 quarters. The position peaked at $504K in Q2 2022. 55 funds tracked by Wall St. Rank hold ADVM as of Q1 2023.

Ergoteles reported no remaining Adverum Biotechnologies position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 8,250 Adverum Biotechnologies shares in Q1 2023, an estimated $47.8K.
Ergoteles first reported a position in Adverum Biotechnologies in Q2 2021 and held it in 5 quarters.
Ergoteles's Adverum Biotechnologies position peaked at $504K in Q2 2022.
55 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.